Latest Conference Articles

January 31st 2014, 8:32am

Genitourinary Cancers Symposium (ASCO GU)

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

January 31st 2014, 7:02am

Genitourinary Cancers Symposium (ASCO GU)

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

January 30th 2014, 10:57am

Genitourinary Cancers Symposium (ASCO GU)

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

January 30th 2014, 10:06am

Genitourinary Cancers Symposium (ASCO GU)

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

January 29th 2014, 2:46pm

Genitourinary Cancers Symposium (ASCO GU)

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

January 28th 2014, 3:34pm

Genitourinary Cancers Symposium (ASCO GU)

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

January 28th 2014, 3:03pm

Genitourinary Cancers Symposium (ASCO GU)

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

January 28th 2014, 3:03pm

Genitourinary Cancers Symposium (ASCO GU)

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.

January 20th 2014, 4:03pm

Gastrointestinal Cancers Symposium (ASCO GI)

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

January 20th 2014, 12:46pm

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.

January 20th 2014, 11:02am

Gastrointestinal Cancers Symposium (ASCO GI)

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.

January 17th 2014, 12:38pm

Gastrointestinal Cancers Symposium (ASCO GI)

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

January 17th 2014, 8:42am

Gastrointestinal Cancers Symposium (ASCO GI)

Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.

January 17th 2014, 6:38am

Gastrointestinal Cancers Symposium (ASCO GI)

Smitha Krishnamurthi, MD, discusses the results of the RAINBOW TRIAL

January 14th 2014, 4:01pm

Gastrointestinal Cancers Symposium (ASCO GI)

Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.

January 14th 2014, 3:07pm

Gastrointestinal Cancers Symposium (ASCO GI)

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.

January 14th 2014, 3:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.

January 14th 2014, 3:00pm

Gastrointestinal Cancers Symposium (ASCO GI)

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

January 14th 2014, 2:59pm

Gastrointestinal Cancers Symposium (ASCO GI)

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

December 16th 2013, 1:51pm

San Antonio Breast Cancer Symposium

Elizabeth Garner, MD, MPH, vice president, Clinical Affairs, Preventive Care, Myriad Genetics, discusses the myRisk Hereditary Cancer Test.